Clinical trials: Immediate Hypersensitivity
Childhood Asthma
Asthma Link: A Real World Application of School Supervised Asthma Therapy
The goal of this study is to assess the feasibility of a clinical trial to evaluate the impact and process of deploying school-supervised asthma therapy in a real-world setting for children with poorly controlled asthma (aged…
- Trial name
- NCT04942379
- Testing
- Asthma Link, Enhanced Usual Care
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Massachusetts, Worcester
Asthma, Healthy Subjects or Volunteers
A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers
The primary objective of this study is to evaluate the pharmacokinetics (PK) and tolerability of tralokinumab when delivered subcutaneously at different flow rates to healthy volunteers.
- Trial name
- NCT02085473
- Testing
- Tralokinumab 300 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Asthma
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)
This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled, parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate (F)[MF/F] metered dose inhaler (MDI) versus MF for…
- Trial name
- NCT00383240
- Testing
- mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID, Mometasone furoate MDI (MF MDI) 200 mcg, formoterol fumarate 10 mcg
- Volunteers
- 781 people
- Sponsor
- Organon and Co
Food Hypersensitivity
A Study of Sublingual Immunotherapy in Peanut-allergic Children
The specific aim of this study is to determine if peanut allergen-specific SLIT will cause clinical desensitization and tolerance to develop in peanut-allergic young children.
- Trial name
- SLB (NCT00597727)
- Testing
- Peanut SLIT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients
The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 μg/day or 800 μg/day…
- Trial name
- NCT00855959
- Testing
- Budesonide, Pulmicort Turbuhaler
- Where
- 6 sites in Japan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
Asthma
Impact of Tiotropium Add-on Therapy in Patients With Asthma
To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
- Trial name
- NCT03964220
- Testing
- Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist
- Where
- United States
- Volunteers
- 7,857 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
This study planned to assess the effect on the reduction in rate of severe asthma exacerbations of different dose levels of QGE031 in asthma patients that are inadequately controlled with inhaled steroid plus beta-2 agonist…
- Trial name
- NCT02336425
- Testing
- QGE031
- Where
- 37 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Urticaria
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
This is a Phase II, multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with Chronic Spontaneous Urticaria (CSU) who have completed the treatment period in a…
- Trial name
- NCT03693625
- Testing
- GDC-0853
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Rhinitis, Allergic, Seasonal
An Exploratory Study of PQ Grass 27600 SU
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting.
- Trial name
- NCT04687059
- Testing
- PQ Grass
- Where
- 14 sites in United States, Germany
- Volunteers
- 119 people
- Sponsor
- Allergy Therapeutics
Asthma
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in…
- Trial name
- NCT06261957
- Testing
- Salbutamol HFA-134a, Salbutamol HFA-152a
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 471 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
- Trial name
- NCT03517566
- Testing
- ZPL389 3mg, ZPL389 10mg, ZPL389 30mg
- Where
- 89 sites in United States, Austria and 14 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Breathing Counts: Evaluating Adherence in the Presence of Asthma Navigation Support
To determine if an asthma navigator is helpful in improving communication between care providers and improving patient adherence to asthma medications after an asthma exacerbation.
- Trial name
- NCT03065205
- Testing
- Propeller Health device + asthma navigator
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Colorado, Denver
Asthma
Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist
The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and…
- Trial name
- NCT01914757
- Testing
- Benralizumab
- Where
- 214 sites in United States, Argentina and 9 more
- Volunteers
- 2,508 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine
- Trial name
- NCT00435461
- Testing
- Fluticasone furoate and fexofenadine
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
- Trial name
- NCT01238861
- Testing
- Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg
- Where
- 74 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- MedImmune LLC
Conjunctivitis, Allergic
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a…
- Trial name
- NCT01289431
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Bausch & Lomb Incorporated
Atopic Dermatitis
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than 24 months of age with mild-to-moderate AD.
- Trial name
- NCT03356977
- Testing
- Crisaborole ointment 2%
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 137 people
- Sponsor
- Pfizer
Asthma
Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma
To test the preliminary efficacy of the TASC adherence promotion intervention for adolescents with asthma in a feasibility randomized controlled trial compared to treatment as usual control arm.
- Trial name
- TASC (NCT04365556)
- Testing
- TASC Intervention
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.